{"product_id":"global-gene-therapy-for-cns-disorders-market-growth-status-and-outlook-2023-2029","title":"Global Gene Therapy for CNS Disorders Market Growth (Status and Outlook) 2023-2029","description":"\u003cp\u003eGlobal Gene Therapy for CNS Disorders Market Growth (Status and Outlook) 2023-2029\u003c\/p\u003e\n\n\u003cp\u003eGene Therapy is an experimental treatment that involves introducing genetic material into a person’s cells to fight or prevent disease. A gene can be delivered to a cell using a carrier known as a “vector.” The most common types of vectors used in gene therapy are viruses. The viruses used in gene therapy are altered to make them safe, although some risks still exist with gene therapy. The technology is still in its infancy.\u003c\/p\u003e\n\n\u003cp\u003eLPI (LP Information)' newest research report, the “Gene Therapy for CNS Disorders Industry Forecast” looks at past sales and reviews total world Gene Therapy for CNS Disorders sales in 2022, providing a comprehensive analysis by region and market sector of projected Gene Therapy for CNS Disorders sales for 2023 through 2029. With Gene Therapy for CNS Disorders sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Gene Therapy for CNS Disorders industry.\u003c\/p\u003e\n\n\u003cp\u003eThis Insight Report provides a comprehensive analysis of the global Gene Therapy for CNS Disorders landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M\u0026amp;A activity. This report also analyzes the strategies of leading global companies with a focus on Gene Therapy for CNS Disorders portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Gene Therapy for CNS Disorders market.\u003c\/p\u003e\n\n\u003cp\u003eThis Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Gene Therapy for CNS Disorders and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Gene Therapy for CNS Disorders.\u003c\/p\u003e\n\n\u003cp\u003eThe global Gene Therapy for CNS Disorders market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.\u003c\/p\u003e\n\n\u003cp\u003eUnited States market for Gene Therapy for CNS Disorders is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.\u003c\/p\u003e\n\n\u003cp\u003eChina market for Gene Therapy for CNS Disorders is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.\u003c\/p\u003e\n\n\u003cp\u003eEurope market for Gene Therapy for CNS Disorders is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.\u003c\/p\u003e\n\n\u003cp\u003eGlobal key Gene Therapy for CNS Disorders players cover Gilead (Kite Pharma), Amgen (BioVex), Novartis, Roche (Spark Therapeutics) and Bluebird Bio, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.\u003c\/p\u003e\n\n\u003cp\u003eThis report presents a comprehensive overview, market shares, and growth opportunities of Gene Therapy for CNS Disorders market by product type, application, key players and key regions and countries.\u003c\/p\u003e\n\n\u003cp\u003eMarket Segmentation:\u003c\/p\u003e\n\n\u003cp\u003eSegmentation by type\u003cbr\u003e\nEx Vivo\u003cbr\u003e\nIn Vivo\u003c\/p\u003e\n\n\u003cp\u003eSegmentation by application\u003cbr\u003e\nHospitals\u003cbr\u003e\nClinics\u003cbr\u003e\nOthers\u003c\/p\u003e\n\n\u003cp\u003eThis report also splits the market by region:\u003cbr\u003e\nAmericas\u003cbr\u003e\nUnited States\u003cbr\u003e\nCanada\u003cbr\u003e\nMexico\u003cbr\u003e\nBrazil\u003cbr\u003e\nAPAC\u003cbr\u003e\nChina\u003cbr\u003e\nJapan\u003cbr\u003e\nKorea\u003cbr\u003e\nSoutheast Asia\u003cbr\u003e\nIndia\u003cbr\u003e\nAustralia\u003cbr\u003e\nEurope\u003cbr\u003e\nGermany\u003cbr\u003e\nFrance\u003cbr\u003e\nUK\u003cbr\u003e\nItaly\u003cbr\u003e\nRussia\u003cbr\u003e\nMiddle East \u0026amp; Africa\u003cbr\u003e\nEgypt\u003cbr\u003e\nSouth Africa\u003cbr\u003e\nIsrael\u003cbr\u003e\nTurkey\u003cbr\u003e\nGCC Countries\u003c\/p\u003e\n\n\u003cp\u003eThe below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.\u003cbr\u003e\nGilead (Kite Pharma)\u003cbr\u003e\nAmgen (BioVex)\u003cbr\u003e\nNovartis\u003cbr\u003e\nRoche (Spark Therapeutics)\u003cbr\u003e\nBluebird Bio\u003c\/p\u003e\n\n\u003cp\u003ePlease note: The report will take approximately 2 business days to prepare and deliver.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"March, 2023 \/ 85 Pages \/ MCW16228571","offer_id":47646867718450,"sku":null,"price":4392.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/www.hardmanwell.com\/products\/global-gene-therapy-for-cns-disorders-market-growth-status-and-outlook-2023-2029","provider":"HARDMAN AND WELL MANAGEMENT CONSULTANCIES L.L.C","version":"1.0","type":"link"}